Symposium

Cancer Rehabilitation

Health Services Research

The Development and Implementation of Standardized Rehabilitation Assessment and Monitoring of Patients Receiving CAR-T Infusion (826939)

Presenter(s)

• 

  Melora A. Rennie, OTR/L, CLT-LANA

  Occupational Therapist
  Northside Hospital
  Atlanta, Georgia

  Presentation Slides Handouts Presentation + Audio
• 

  Aneesha Virani, PhD, CCC-SLP

  Clinical Coordinator of Rehabilitation Services
  Northside Hospital
  Atlanta, Georgia

Non-presenting Author(s)

• PH

  Prentice Haugh, PT, CLT-LANA

  Physical Therapist
  Northside Hospital
  Roswell, Georgia
• BP

  Brooke Paige, DPT

  Inpatient Rehab Supervisor
  Northside Hospital
  Atlanta, Georgia
• SC

  Sarah Crock, MEd, CCC-SLP

  Speech-Language Pathologist
  Northside Hospital
  Atlanta, Georgia

Northside Hospital Cancer Institute is among select centers in the country offering chimeric antigen receptor (CAR) T-cell therapy for patients with certain types of lymphoma and acute leukemia who have failed previous methods of treatment. Patients receiving CAR-T cell therapy are at risk for cytokine release syndrome (CRS) and neurotoxicity which can significantly impact their cognitive, neurological and physical functioning requiring prolonged hospitalization and intensive rehabilitation. Due to the patient’s high risk for functional decline, the need for a comprehensive baseline evaluation completed by rehabilitation disciplines of OT, PT and ST prior to CAR-T cell infusion was identified to aid healthcare professionals discern which deficits were attributed to CAR-T cell infusion. This symposium will discuss the development and implementation of this pilot study and review the findings.

Learning Objectives:

• Discuss the impact CAR-T infusion can have on a patient’s level of function.
• Discuss the development of an acute care rehabilitation driven evaluation and monitoring process for CAR-T patients.
• Discuss the importance of intervention from occupational, physical and speech therapy disciplines in order for CAR-T cell patients to maintain the highest level of independence.